DK1147110T3 - Pyrazino(aza)indolderivater - Google Patents

Pyrazino(aza)indolderivater

Info

Publication number
DK1147110T3
DK1147110T3 DK00901240T DK00901240T DK1147110T3 DK 1147110 T3 DK1147110 T3 DK 1147110T3 DK 00901240 T DK00901240 T DK 00901240T DK 00901240 T DK00901240 T DK 00901240T DK 1147110 T3 DK1147110 T3 DK 1147110T3
Authority
DK
Denmark
Prior art keywords
pyrazino
aza
indole derivatives
disorders
nervous system
Prior art date
Application number
DK00901240T
Other languages
Danish (da)
English (en)
Inventor
David Reginald Adams
Jon Mark Bentley
James Davidson
Matthew Alexander Jame Duncton
Richard Hugh Phillip Porter
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of DK1147110T3 publication Critical patent/DK1147110T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
DK00901240T 1999-01-29 2000-01-28 Pyrazino(aza)indolderivater DK1147110T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9902047.1A GB9902047D0 (en) 1999-01-29 1999-01-29 Chemical compounds XI
PCT/GB2000/000244 WO2000044753A1 (en) 1999-01-29 2000-01-28 Pirazino(aza)indole derivatives

Publications (1)

Publication Number Publication Date
DK1147110T3 true DK1147110T3 (da) 2003-09-01

Family

ID=10846774

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00901240T DK1147110T3 (da) 1999-01-29 2000-01-28 Pyrazino(aza)indolderivater

Country Status (18)

Country Link
US (4) US6800627B1 (de)
EP (1) EP1147110B1 (de)
JP (1) JP2002535408A (de)
KR (1) KR100633375B1 (de)
CN (2) CN100418968C (de)
AT (1) ATE239731T1 (de)
AU (1) AU758685B2 (de)
BR (1) BR0008979A (de)
CA (1) CA2359034A1 (de)
DE (1) DE60002554T2 (de)
DK (1) DK1147110T3 (de)
ES (1) ES2199132T3 (de)
GB (1) GB9902047D0 (de)
MX (1) MXPA01007643A (de)
PT (1) PT1147110E (de)
TR (1) TR200102161T2 (de)
WO (1) WO2000044753A1 (de)
ZA (1) ZA200106202B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU8395501A (en) * 2000-07-31 2002-02-13 Hoffmann La Roche Piperazine derivatives
CA2428905A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab PIPERAZINYLPYRAZINE COMPOUNDS FOR USE AS ANTAGONISTS OF THE SEROTONIN 5-HT2 RECEPTOR
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
EP1343768A1 (de) * 2000-12-20 2003-09-17 Bristol-Myers Squibb Pharma Company Aryl und aminoaryl substituierte serotonin rezeptor agonist und antagonistliganden
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
CA2447156A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
CA2447479A1 (en) 2001-06-01 2002-12-12 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
MXPA03010807A (es) 2001-06-01 2004-11-22 Alcon Inc Piranoidazoles y su uso para el tratamiento del glaucoma.
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
WO2004000830A1 (en) 2002-06-19 2003-12-31 Biovitrum Ab Novel compounds, their use and preparation
CA2506204A1 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
MXPA05012547A (es) * 2003-05-21 2006-05-25 Prosidion Ltd Inhibidores de amida de acido pirrolopiridina-2-carboxilico de fosforilasa de glucogeno.
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
EP2248524A3 (de) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
ATE514698T1 (de) * 2005-05-03 2011-07-15 Hoffmann La Roche Tetracyclische azapyrazinoindoline als 5-ht2- liganden
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
CN101331131A (zh) 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
EP2742936A1 (de) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Kondensierte heterocyclische Verbindung und ihre Verwendung
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
ES2588193T3 (es) 2008-03-28 2016-10-31 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidro-2H-pirazino[1,2-a]indol-1-ona activos como inhibidores de cinasa, proceso para su preparación y composiciones farmacéuticas que los comprenden
EP2510949A4 (de) 2009-12-11 2013-11-13 Astellas Pharma Inc Therapeutikum für fibromyalgie
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
MX363662B (es) * 2012-10-08 2019-03-27 Centro De Investig Y De Estudios Avanzados Del I P N Star Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JP6217561B2 (ja) * 2014-08-21 2017-10-25 信越化学工業株式会社 新規オニウム塩化合物及びレジスト組成物並びにパターン形成方法
EP3733204A4 (de) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited Therapeutikum für belastungsinkontinenz und stuhlinkontinenz
CA3159791A1 (en) * 2019-10-31 2021-05-06 Holosmedic Hexahydro-2h-pyrazino[1,2-a]pyrazine-6,9-dione derivatives and pharmaceutical compositions for prevention or treatment of cancer comprising same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792724A (fr) * 1971-12-16 1973-06-14 Merck Patent Gmbh Derives de pyrazinoindole et leur procede de preparation
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819032D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds IV
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii

Also Published As

Publication number Publication date
KR100633375B1 (ko) 2006-10-16
ZA200106202B (en) 2002-07-29
US6800627B1 (en) 2004-10-05
EP1147110A1 (de) 2001-10-24
TR200102161T2 (tr) 2002-05-21
ATE239731T1 (de) 2003-05-15
KR20010101873A (ko) 2001-11-15
CN1837207A (zh) 2006-09-27
WO2000044753A1 (en) 2000-08-03
US20040092525A1 (en) 2004-05-13
PT1147110E (pt) 2003-09-30
US20040039200A1 (en) 2004-02-26
CA2359034A1 (en) 2000-08-03
ES2199132T3 (es) 2004-02-16
CN1289499C (zh) 2006-12-13
CN100418968C (zh) 2008-09-17
MXPA01007643A (es) 2003-06-24
JP2002535408A (ja) 2002-10-22
US20060160816A1 (en) 2006-07-20
DE60002554T2 (de) 2004-03-25
CN1337963A (zh) 2002-02-27
US7145009B2 (en) 2006-12-05
DE60002554D1 (de) 2003-06-12
GB9902047D0 (en) 1999-03-17
AU2119600A (en) 2000-08-18
EP1147110B1 (de) 2003-05-07
AU758685B2 (en) 2003-03-27
BR0008979A (pt) 2002-02-05

Similar Documents

Publication Publication Date Title
ATE239731T1 (de) Pyrazino(aza)indolderivate
JO2282B1 (en) Oxazole derivatives
CA2432085A1 (en) Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
TNSN04136A1 (en) Aza-arylpiperazines
BR0014178A (pt) Derivados de ácido dicarboxìlico com propriedades farmacêuticas
TR200100659T2 (tr) 5-HT2C agonistleri olarak piroloindoller, piridoindoller ve azepinoindoller.
TR200200649T2 (tr) Farmasötik özelliklere sahip olan yeni aminodikarboksilik asit türevleri
NO20065904L (no) Terapeutiske forbindelser
RS20050462A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
MY127066A (en) Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors.
NO20044501L (no) [1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler
NO20055655D0 (no) Anvendelse av azetidinkarboksamidderivater i terapi
WO2002072584A3 (en) Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders
GB0314967D0 (en) Piperazine derivatives
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
ATE389655T1 (de) Pyrimidinderivate
SE9902267D0 (sv) New compounds
MX2008001033A (es) Derivados de 4-ariloxi quinolina como moduladores de 5-ht6.
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
MXPA03002914A (es) Compuestos quimicos.
TW200510399A (en) 1, 3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
TW200514779A (en) Imidazole derivatives III
MY136138A (en) Hexacyclic compounds